Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 6 Issue 2

A Study on Clinicopathological Features of Covid-19 Among Vaccinated and Non-vaccinated People

Rakesh Holla A1*, Amit Sharma2 and Naveen Chawla3

1Department of Pathology, Military Hospital, District Cachar, Silchar, Assam, India
2Department of Pathology, Sampurna Sodani Diagnostics, Dhar, Madhya Pradesh, India
3Department of Pathology, INHS Asvini, RC Church, Colaba, Mumbai, Maharashtra, India

*Corresponding Author: Rakesh Holla A, Department of Pathology, Military Hospital, District Cachar, Silchar, Assam, India.

Received: December 09, 2021; Published: January 07, 2022

Abstract

Introduction: The World Health Organisation declared Covid-19 outbreak by SARS-CoV-2 as a global Public Health Emergency of International Concern under the International Health Regulations on 30 January 2020 and was then further characterized as a pandemic on 11 March 2020. The pandemic has since then swept the globe as an unprecedented event causing widespread disruption and mayhem in terms of economic upheaval and health care ruin, dredging up the fragility of health services and public health systems worldwide. The Government of India (GoI) introduced new vaccines for mass vaccination against SARS-CoV-2 with the intent to keep the menace of the virus pandemic at bay and included Covishield (the name employed in India for the Oxford-AstraZeneca vaccine), a non-replicating, adenovirus vector vaccine carrying a recombinant spike protein of SARS-CoV-2. The situation in India in the April and May months of 2021 mandated a unified and comprehensive response by everyone at the helm when the country was struck by the second wave of Covid-19. An observational study was carried out to assess the course and the effects of SARS-CoV2 on the biochemical and haematological profile of Covid-19 patients and to draw comparisons between the vaccinated and non-vaccinated groups of people.

Method: The study was carried out at two different locations in India for two different groups of population, one vaccinated against Covid-19 by two doses of Covishield vaccine while the other group which was not being vaccinated against Covid-19. The non-vaccinated group comprised entirely of civilian population at Bihta, state of Bihar in India who were referred by the government medical hospital to a Covid hospital established by the Indian Army. The vaccinated group comprised of those vaccinated against Covid-19 with two doses, atleast 28 days apart, of Covishield vaccine. A total of 138 Covid-19 patients, 78 covid-19 patients of non-vaccinated group and 60 Covid-19 patients of vaccinated group were studied between 01 May 2021 and 31 July 2021. The patients were evaluated in terms of clinical presentation, haematological and biochemical laboratory parameters including inflammatory markers and mortality rates.

Result: The study reveals that the vaccinated cohort with breakthrough infections following Covid-19 vaccination with two doses of Covishield Vaccine had only mild symptoms and no deaths being reported while the non-vaccinated cohort presented with moderate to severe Covid-19, deranged laboratory parameters and increased mortality rate.

Conclusion: The study clearly demonstrates that Covid-19 vaccination with two doses of Covishield vaccine, offers significant protection against severe infections and death from Covid-19. While the study highlights the importance of Covid-19 vaccination particularly amongst the high risk groups such as those with co-morbid conditions including obesity, diabetes mellitus, hypertension, etc., it also emphasizes the need for observing Covid appropriate behaviour such as social distancing, frequent hand hygiene and wearing of face mask as breakthrough infections were noted amongst the vaccinated cohort in this study for want of such measures in the milieu.

Keywords: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2); Covid-19 Vaccination; Covishield Vaccine; Breakthrough Infections; Neutrophil Lymphocyte Ratio; Delta Variant; Inflammatory Markers

References

  1. “Diagnostics, therapeutics, vaccine readiness and other health products for Covid-19”. WHO Interim guidance document (2020).
  2. Pandi-Perumal S R., et al. “Dealing with a pandemic: the Kerala model of containment strategy for COVID-19”. Pathogens and Global Health 114 (2020): 232-233.
  3. Gulia K K and Kumar V M. “Reverse quarantine in Kerala: managing the 2019 novel coronavirus in a state with a relatively large elderly population”. Psychogeriatrics 20 (2020): 794-795.
  4. Kumar VM., et al. “Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases”. NPJ Vaccines 6 (2021): 60.
  5. Sanjeet Bagcchi. “The world's largest COVID-19 vaccination campaign”. Lancet Infectious Disease3 (2021): 323.
  6. Mohandas S., et al. “Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model”. iScience 2 (2021): 102054.
  7. Folegatti PM., et al. “Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial”. Lancet 10249 (2021): 467e478.
  8. Voysey M., et al. “Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARSCoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK”. Lancet 10269 (2021): 99e111.
  9. Francone M., et al. “Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis”. European Radiology12 (2020): 6808-6817.
  10. Planas D., et al. “Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization”. Nature 596 (2021): 276-280.
  11. Lopez Bernal J., et al. “Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant”. The New England Journal of Medicine 7 (2021): 585-594.
  12. Moya A., et al. “The population genetics and evolutionary epidemiology of RNA viruses”. Nature Reviews Microbiology 2 (2004): 279-288.
  13. World Health Organisation: India situation update report- 65, Covid-19; WHO.int; India; emergencies; 28 Apr 21.
  14. Indian Genomic Consortium for COVID19 has shared the Genome Sequencing data with States multiple times from 26th March 2021 onwards; Press information Bureau, GoI, Ministry of Health and Family Welfare; 16 Apr (2021).
  15. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet 10229 (2020): 1054-1062.
  16. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. JAMA11 (2020): 1061-1069.
  17. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet10223 (2020): 497-506.
  18. Elena Aloisio., et al. “A Comprehensive appraisal of laboratory biochemistry tests as major predictors of Covid-19 severity”. Archives of Pathology and Laboratory Medicine 144 (2020): 1457-1464.
  19. Ai-Ping Yang., et al. “The diagnostic and predictive role of NLR, d-NLR and PLR in Covid-19 patients”. International Immunopharmocology 84 (2020): 106504.
  20. Joachim Linssen., et al. “A novel haemocytometric Covid-19 prognostic score developed and validated in an observational multicentre European hospital-based study”. eLife 9 (2020): e63195.
  21. Michal Kukla., et al. “Covid-19, MERS and SARS with concomitant Liver Injury- systematic review of the existing literature”. Journal of Clinical Medicine 9 (2020): 1420.
  22. Zhang Y., et al. “Liver Impairment in Covid-19 patients: A retrospective analysis of 115 cases from a single center in Wuhan city, China”. Liver International (2020).
  23. Alene M., et al. “Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis”. PLOS ONE3 (2021): e0249090.
  24. Ghosh S., et al. “Covishield (AZD1222) Vaccine Effectiveness among healthcare and frontline workers of Indian Armed Forces”. Medical Journal Armed Forces India 77 (2021): S264-S270.
  25. Michel JM., et al. “Covid-19 vaccines dampen genomic diversity of SARS-CoV-2: Unvaccinated patients exhibit more antigenic mutational variance”. MedRxiv (2020).

Citation

Citation: Rakesh Holla A., et al. “A Study on Clinicopathological Features of Covid-19 Among Vaccinated and Non-vaccinated People”.Acta Scientific Medical Sciences 6.2 (2022): 18-31.

Copyright

Copyright: © 2022 Rakesh Holla A., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is November 30, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US